Weight care, medically guided.

Four treatment paths, one membership. A licensed provider evaluates which, if any, is right for you, and a coach supports you throughout.

Every membership includes coaching. Whatever your provider decides, a Concorde-powered coach is part of the plan, check-ins, side-effect navigation, and habit support are built in, not an upsell.
What the research shows
15-20%

Average body-weight loss in year-long clinical trials of semaglutide and tirzepatide.*

Alongside diet and exercise changes, versus roughly 2-4% with lifestyle changes alone. Individual results vary, and eligibility is always a licensed provider's decision.

Your current weight220 lbs
What trial participants lost at that weight33-44 lbs

A research reference, not a prediction or promise. Your plan and outcome depend on your provider's evaluation.

See if you're eligible

Safety info: GLP-1 medications may have serious side effects, including possible thyroid tumors. Do not use if you or your family have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). See full warnings and safety information.

* Wilding et al., NEJM (2021), semaglutide 2.4 mg (STEP 1): ~15% mean weight loss at 68 weeks. Jastreboff et al., NEJM (2022), tirzepatide 15 mg (SURMOUNT-1): ~20% mean weight loss at 72 weeks. Trials studied FDA-approved formulations in adults with obesity or overweight with a weight-related condition; compounded medications were not the studied products.

Find out what's right for you.

A licensed provider makes the call, the assessment is where it starts.

Get Started